Abstract
Apart from cigarette smoking, hypertension and hyperlipidaemia are major risk factors for atherosclerosis and coronary heart disease. However, β-adrenoceptor antagonists, given to reduce Mood pressure, may have an adverse effect on lipid profiles — a swapping of one risk factor for another! In contrast, antihypertensive α 1-adrenoceptar antagonists have potentially beneficial effects on lipid metabolism . Henry Elliott analyses the complex adrenergic control of lipid metabolism and focuses on the benefits (e.g. reduced incidence of atherosclerosis, reduced risk of coronary heart disease) that might be gained from clinical use of α 1-adrenoceptor antagonists in antihypertensive therapy .
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call